4//SEC Filing
Rasbach Kyle 4
Accession 0001415889-25-001859
CIK 0001907108other
Filed
Jan 21, 7:00 PM ET
Accepted
Jan 22, 4:55 PM ET
Size
7.7 KB
Accession
0001415889-25-001859
Insider Transaction Report
Form 4
Rasbach Kyle
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2025-01-17+245,250→ 245,250 totalExercise: $5.07Exp: 2035-01-16→ Common Stock (245,250 underlying) - Award
Common Stock
2025-01-17+40,875→ 40,875 total
Footnotes (3)
- [F1]The reported securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. Twenty-five percent (25%) of the RSUs shall vest on February 15, 2026, and 1/16th of the RSUs shall vest in quarterly installments thereafter on the Issuer's standard quarterly vesting dates, subject to the Reporting Person's continued service through each applicable vesting date.
- [F2]The reported securities are RSUs.
- [F3]25% of the shares underlying the option vest and become exercisable on December 18, 2025, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.
Documents
Issuer
Lexeo Therapeutics, Inc.
CIK 0001907108
Entity typeother
Related Parties
1- filerCIK 0002050086
Filing Metadata
- Form type
- 4
- Filed
- Jan 21, 7:00 PM ET
- Accepted
- Jan 22, 4:55 PM ET
- Size
- 7.7 KB